<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01582360</url>
  </required_header>
  <id_info>
    <org_study_id>2011/10076</org_study_id>
    <secondary_id>2011/10076 (OUSH)</secondary_id>
    <nct_id>NCT01582360</nct_id>
  </id_info>
  <brief_title>2012_PharmacoCRRT-study:Pharmacokinetics of Anti-infectives in Critically Ill Patients in Need of Continuous Renal Replacement Therapy (CRRT)</brief_title>
  <acronym>PharmacoCRRT</acronym>
  <official_title>Pharmacokinetics of Anti-infectives in Critically Ill Patients in Need of Continuous Renal Replacement Therapy (CRRT) or Without CRRT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to examine if changes in pharmacokinetics of important
      antiinfectives in Critically Ill patients in need of continuous renal replacement therapy
      (CRRT), causes inadequate concentrations in plasma.

      The effect of different modus of CRRT: CVVH and CVVHD will be compared, as well as type of
      filter, filter lifetime etc.

      Hypothesis: The risk of incorrect dosage of antiinfectives - to low/ to high- is increased in
      critically ill patients receiving CRRT. Inadequate plasma concentrations of antiinfectives
      may contribute to increased mortality in this group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of the study is to examine if changes in pharmacokinetics of important
      antiinfectives in Critically Ill patients in need of continuous renal replacement therapy
      (CRRT), causes inadequate concentrations in plasma.

      The effect of different modus of CRRT: CVVH and CVVHD will be compared, as well as type of
      filter, filter lifetime etc.

      Hypothesis: The risk of incorrect dosage of antiinfectives - to low/ to high- is increased in
      critically ill patients receiving CRRT. Inadequate plasma concentrations of antiinfectives
      may contribute to increased mortality in this group.

      The antiinfectives to be examined are meropenem, fluconazol, cefotaxim, ciprofloxacin,
      tazobactam-piperacillin, vancomycin,penicillin,cloxacillin.

      Endpoints:

        1. Measured plasma concentrations of antiinfectives are sufficient for maximal microbial
           killing.

        2. To identify the most important variability factors for plasma concentrations of
           antiinfectives in patients receiving CRRT

        3. Establish and validate a routine for measurement of vital antiinfectives.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sub-therapeutic levels of measured antiinfectiva</measure>
    <time_frame>72 hours</time_frame>
    <description>Pharmacokinetic/pharmacodynamic index achieved for each antiinfectiva</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SOFA-score</measure>
    <time_frame>72 hrs</time_frame>
    <description>Sequential organ failure assessment, first 3 days after initiation of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90-days</time_frame>
  </secondary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">640</enrollment>
  <condition>Critically Ill</condition>
  <condition>Acute Renal Failure</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>antiinfectiva: vancomycin</arm_group_label>
    <description>80 patients Completed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antiinfectiva: meropenem</arm_group_label>
    <description>80 patients recruiting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antiinfectiva: flukonazol</arm_group_label>
    <description>80 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antiinfectiva: cefotaxim</arm_group_label>
    <description>80 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antiinfectiva: benzylpenicilline</arm_group_label>
    <description>80 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antiinfectiva: tazobactam piperacillin</arm_group_label>
    <description>80 patients recruiting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antiinfectiva: cloxacillin</arm_group_label>
    <description>80 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antiinfectiva: ciprofloxacin</arm_group_label>
    <description>80 patients</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients admitted to the ICU at Oslo University Hospital, in need of
        treatment with antiinfectives.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients admitted to ICU in need of antiinfectives:

               1. in need of CRRT

               2. without acute kidney failure

          2. requirement for antiinfectives&gt; 72 hrs

          3. Age &gt; 18 yrs

          4. signed informed consent

        Exclusion Criteria:

          1. Acute or chronic renal failure not in need of CRRT

          2. Age &lt; 18 yrs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elin Helset, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Fr Bugge, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth von der Lippe, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hilde Ma Sporsem, cand pharm</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sykehusapotekene Oslo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yvonne Lao, cand pharm</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sykehusapotekene Oslo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elin Helset, MD PhD</last_name>
    <phone>+4722119585</phone>
    <email>ehj@ous-hf.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elin Helset, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Fr Bugge, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hilde Ma Sporsem, cand pharm</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yvonne Lao, cand pharm</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kirsti Andersson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>October 14, 2015</last_update_submitted>
  <last_update_submitted_qc>October 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>critical illness</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>CRRT</keyword>
  <keyword>CVVH</keyword>
  <keyword>CVVHD</keyword>
  <keyword>CVVHDF</keyword>
  <keyword>antiinfectives</keyword>
  <keyword>antibiotics</keyword>
  <keyword>minimum inhibitory concentration</keyword>
  <keyword>bacterial killing</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>PK/PD index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

